1, terbio is suitable for thrombocytopenia (CIT) and immune thrombocytopenia (ITP) caused by chemotherapy in adults and children. The data shows that 30% of ITP is a long-term chronic disease, and the annual mortality rate of 10 is 10-20%, which is beneficial to pharmaceutical companies.
2.Ebbio has three indications: anemia caused by chronic kidney disease (CKD), anemia caused by red blood cell mobilization during perioperative period and chemotherapy (CIA). CKD is a chronic disease, and there is no cure at present, so we can only do dialysis or directly exchange kidneys.